Genprex Stock Performance
| GNPX Stock | USD 2.26 0.01 0.44% |
The company retains a Market Volatility (i.e., Beta) of 1.45, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genprex will likely underperform. Genprex has an expected return of -1.63%. Please make sure to check out Genprex jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Genprex performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genprex has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
Five Day Return 4.15 | Year To Date Return (75.85) | Ten Year Return (98.80) | All Time Return (98.80) |
Last Split Factor 1:40 | Last Split Date 2024-02-02 |
1 | Disposition of 1126 shares by Ryan Confer of Genprex at 4.4 subject to Rule 16b-3 | 02/16/2024 |
2 | Payment of 2642 shares by John Varner of Genprex subject to Rule 16b-3 | 02/21/2024 |
3 | Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the ... | 03/06/2024 |
4 | Genprex Adds Korean Patent for Leading Drug Candidate to IP Portfolio - The Globe and Mail | 03/14/2024 |
5 | Genprex Announces 6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 03/19/2024 |
6 | Genprex Announces Closing of 6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 03/22/2024 |
7 | Brokers Issue Forecasts for Genprex, Inc.s FY2023 Earnings - Defense World | 03/27/2024 |
8 | Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System | 04/02/2024 |
9 | Genprex Expands SCLC Study of Key Candidate, Stock Up | 04/04/2024 |
10 | Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Trea... | 04/09/2024 |
| Begin Period Cash Flow | 21 M |
Genprex |
Genprex Relative Risk vs. Return Landscape
If you would invest 734.00 in Genprex on February 1, 2024 and sell it today you would lose (507.00) from holding Genprex or give up 69.07% of portfolio value over 90 days. Genprex is currently does not generate positive expected returns and assumes 6.4596% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Genprex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genprex Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genprex's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genprex, and traders can use it to determine the average amount a Genprex's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2526
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GNPX |
Estimated Market Risk
| 6.46 actual daily | 57 57% of assets are less volatile |
Expected Return
| -1.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genprex is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genprex by adding Genprex to a well-diversified portfolio.
Genprex Fundamentals Growth
Genprex Stock prices reflect investors' perceptions of the future prospects and financial health of Genprex, and Genprex fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genprex Stock performance.
| Return On Equity | -2.08 | ||||
| Return On Asset | -1.09 | ||||
| Current Valuation | (2.4 M) | ||||
| Shares Outstanding | 1.91 M | ||||
| Price To Earning | (1.09) X | ||||
| Price To Book | 0.69 X | ||||
| EBITDA | (31.06 M) | ||||
| Net Income | (30.86 M) | ||||
| Cash And Equivalents | 25.52 M | ||||
| Cash Per Share | 0.53 X | ||||
| Debt To Equity | 1.11 % | ||||
| Current Ratio | 10.71 X | ||||
| Book Value Per Share | 4.99 X | ||||
| Cash Flow From Operations | (24.74 M) | ||||
| Earnings Per Share | (22.56) X | ||||
| Market Capitalization | 4.34 M | ||||
| Total Asset | 10.67 M | ||||
| Retained Earnings | (133.69 M) | ||||
| Working Capital | 4.28 M | ||||
| Current Asset | 964.42 K | ||||
| Current Liabilities | 587.7 K | ||||
About Genprex Performance
To evaluate Genprex Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Genprex generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Genprex Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Genprex market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Genprex's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 43.4 K | 28.3 K | |
| Return On Tangible Assets | (3.12) | (3.27) | |
| Return On Capital Employed | (4.19) | (4.40) | |
| Return On Assets | (2.89) | (3.04) | |
| Return On Equity | (4.16) | (4.37) |
Things to note about Genprex performance evaluation
Checking the ongoing alerts about Genprex for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genprex help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genprex generated a negative expected return over the last 90 days | |
| Genprex has high historical volatility and very poor performance | |
| Genprex has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (30.86 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Genprex currently holds about 25.52 M in cash with (24.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Latest headline from finance.yahoo.com: Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting |
- Analyzing Genprex's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genprex's stock is overvalued or undervalued compared to its peers.
- Examining Genprex's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genprex's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genprex's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genprex's stock. These opinions can provide insight into Genprex's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genprex. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Genprex Stock please use our How to Invest in Genprex guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Genprex Stock analysis
When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Genprex's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genprex. If investors know Genprex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genprex listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (22.56) | Return On Assets (1.09) | Return On Equity (2.08) |
The market value of Genprex is measured differently than its book value, which is the value of Genprex that is recorded on the company's balance sheet. Investors also form their own opinion of Genprex's value that differs from its market value or its book value, called intrinsic value, which is Genprex's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genprex's market value can be influenced by many factors that don't directly affect Genprex's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genprex's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genprex is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genprex's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.